<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1166">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 08, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04371640</url>
  </required_header>
  <id_info>
    <org_study_id>15680</org_study_id>
    <nct_id>NCT04371640</nct_id>
  </id_info>
  <brief_title>Sirolimus in COVID-19 Phase 1</brief_title>
  <acronym>SirCO-1</acronym>
  <official_title>A Randomized, Double-Blinded, Placebo-Controlled Trial Evaluating the Virological Efficacy, Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Sirolimus Adjuvant Therapy in Patients With Coronavirus Disease (COVID-19)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Walter K. Kraft</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Thomas Jefferson University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a double-blinded, two-arm, randomized, placebo controlled study comparing the&#xD;
      virological efficacy of add-on sirolimus with standard care to placebo and standard care.&#xD;
      Virological efficacy is defined as the change from baseline to day 7 in SARS-CoV-2 viral&#xD;
      burden measured by quantitative real-time polymerase chain reaction.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    Study population not regularly admitted to hospital and approaches have shifted away from&#xD;
    repurposing old drugs.&#xD;
  </why_stopped>
  <start_date type="Actual">July 6, 2020</start_date>
  <completion_date type="Anticipated">August 2021</completion_date>
  <primary_completion_date type="Anticipated">July 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in SARS-CoV-2 viral burden from baseline to day 7 of treatment</measure>
    <time_frame>Baseline, and days 1, 2, 3, 4, 5, 6, &amp; 7 post-dose for all patients</time_frame>
    <description>SARS-CoV-2 viral burden will be quantified for both arms using a qRT-PCR</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in SARS-CoV-2 viral burden at days 1-6</measure>
    <time_frame>Days 1, 2, 3, 4, 5, and 6 post-dose for all patients</time_frame>
    <description>SARS-CoV-2 viral burden will be quantified for both arms using a qRT-PCR</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of treatment emergent adverse events</measure>
    <time_frame>Days 1, 2, 3, 4, 5, and 6 post-dose for all patients</time_frame>
    <description>Safety and tolerability of sirolimus in patients with COVID-19</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>SARS-CoV-2</condition>
  <condition>Covid-19</condition>
  <arm_group>
    <arm_group_label>Sirolimus</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Sirolimus + standard medical care Day 1: 10mg Days 2-7: 5mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo + standard medical care Day 1: 10mL Days 2-7: 5mL</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sirolimus 1 MG/ML</intervention_name>
    <description>Oral solution</description>
    <arm_group_label>Sirolimus</arm_group_label>
    <other_name>Rapamune</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Oral solution</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male or non-pregnant female &gt;/=18 and &lt;/=65 years of age at the time of consent&#xD;
&#xD;
          -  Laboratory confirmed SARS-CoV-2 infection&#xD;
&#xD;
          -  Investigator-estimated hospitalization duration of at least 5 days&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Need for &gt;4 liters nasal cannula oxygen to maintain oxygen saturation &gt;90%&#xD;
&#xD;
          -  Hypersensitivity to sirolimus&#xD;
&#xD;
          -  Pregnant or breastfeeding&#xD;
&#xD;
          -  Anticipated transfer to another study hospital within 72 hours&#xD;
&#xD;
          -  Alanine transaminase (ALT) &gt;3 times the upper limit of normal&#xD;
&#xD;
          -  Creatinine clearance &lt;30mL/min as estimated by Cockcroft-Gault&#xD;
&#xD;
          -  Underlying immunosuppression due to daily &gt;5 mg prednisone equivalent a day, prior&#xD;
             solid organ transplant, or other immunosuppression deemed by investigator to be&#xD;
             potentially unsafe&#xD;
&#xD;
          -  Co-administration with strong inhibitors of CYP3A4 and/or P-glycoprotein (P-gp) (such&#xD;
             as ketoconazole, voriconazole, itraconazole, telithromycin, clarithromycin and others)&#xD;
&#xD;
          -  Co-administration with strong inducers of CYP3A4 and/or P-glycoprotein (P-gp) (such as&#xD;
             phenytoin or rifampin)&#xD;
&#xD;
          -  Anticipated surgery within 1 month&#xD;
&#xD;
          -  Need for healing of a fracture or a significant soft tissue wound&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Walter K Kraft, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Thomas Jefferson University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Thomas Jefferson University Hospital</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19107</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>April 28, 2020</study_first_submitted>
  <study_first_submitted_qc>April 28, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">May 1, 2020</study_first_posted>
  <last_update_submitted>December 3, 2020</last_update_submitted>
  <last_update_submitted_qc>December 3, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 7, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Thomas Jefferson University</investigator_affiliation>
    <investigator_full_name>Walter K. Kraft</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sirolimus</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

